References
- Bhat S, Han J. Outcomes of rivaroxaban use in patients with sickle cell disease. Ann Pharmacother. 2017;51(4):357–358.
- Binaghi G, Congia D, Dessì C, et al. Cardiac and thrombotic complications in the peripartum period of a patient affected by β-thalassemia intermedia: an unusual case. Int J Cardiol. 2016;215:32–33.
- Gaertner S, Cordeanu EM, Nouri S, et al. Rivaroxaban versus standard anticoagulation for symptomatic venous thromboembolism (REMOTEV observational study): analysis of 6-month outcomes. Int J Cardiol. 2017;226:103–109.
- Cordeanu M, Gaertner S, Bensalah N, et al. Rivaroxaban induced liver injury: a cholestatic pattern. Int J Cardiol. 2016;216:97–98.
- Succar J, Musallam KM, Taher AT. Thalassemia and venous thromboembolism. Mediterr J Hematol Infect Dis. 2011;3(1):e2011025.
- Sparkenbaugh EM, Chantrathammachart P, Mickelson J, et al. Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood. 2014;123(11):1747–1756.
- Ruf W. FXa takes center stage in vascular inflammation. Blood. 2014;123(11):1630–1631.
- Mekaj YH, Mekaj AY, Duci SB, et al. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;11:967–977.